• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

考虑社会经济剥夺因素的心血管疾病政策模型,用于预测预期寿命。

A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation.

机构信息

Health Economics and Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK.

Robertson Centre for Biostatistics, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK.

出版信息

Heart. 2015 Feb;101(3):201-8. doi: 10.1136/heartjnl-2014-305637. Epub 2014 Oct 16.

DOI:10.1136/heartjnl-2014-305637
PMID:25324535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4316925/
Abstract

OBJECTIVES

A policy model is a model that can evaluate the effectiveness and cost-effectiveness of interventions and inform policy decisions. In this study, we introduce a cardiovascular disease (CVD) policy model which can be used to model remaining life expectancy including a measure of socioeconomic deprivation as an independent risk factor for CVD.

DESIGN

A state transition model was developed using the Scottish Heart Health Extended Cohort (SHHEC) linked to Scottish morbidity and death records. Individuals start in a CVD-free state and can transit to three CVD event states plus a non-CVD death state. Individuals who have a non-fatal first event are then followed up until death. Taking a competing risk approach, the cause-specific hazards of a first event are modelled using parametric survival analysis. Survival following a first non-fatal event is also modelled parametrically. We assessed discrimination, validation and calibration of our model.

RESULTS

Our model achieved a good level of discrimination in each component (c-statistics for men (women)-non-fatal coronary heart disease (CHD): 0.70 (0.74), non-fatal cerebrovascular disease (CBVD): 0.73 (0.76), fatal CVD: 0.77 (0.80), fatal non-CVD: 0.74 (0.72), survival after non-fatal CHD: 0.68 (0.67) and survival after non-fatal CBVD: 0.65 (0.66)). In general, our model predictions were comparable with observed event rates for a Scottish randomised statin trial population which has an overlapping follow-up period with SHHEC. After applying a calibration factor, our predictions of life expectancy closely match those published in recent national life tables.

CONCLUSIONS

Our model can be used to estimate the impact of primary prevention interventions on life expectancy and can assess the impact of interventions on inequalities.

摘要

目的

政策模型是一种可以评估干预措施的有效性和成本效益,并为政策决策提供信息的模型。本研究引入了一种心血管疾病(CVD)政策模型,该模型可以用于模拟剩余预期寿命,包括将社会经济剥夺作为 CVD 的一个独立风险因素进行衡量。

设计

使用苏格兰心脏健康扩展队列(SHHEC)构建状态转移模型,并与苏格兰发病率和死亡率记录相关联。个体从 CVD 无事件状态开始,可以转移到三个 CVD 事件状态和一个非 CVD 死亡状态。首次发生非致命事件的个体随后会被跟踪直至死亡。采用竞争风险方法,使用参数生存分析对首次事件的特定原因风险进行建模。首次非致命事件后的生存情况也采用参数化模型进行建模。我们评估了我们模型的区分度、验证和校准。

结果

我们的模型在每个组成部分都达到了较好的区分度(男性(女性)-非致命性冠心病(CHD)的 C 统计量:0.70(0.74),非致命性脑血管疾病(CBVD):0.73(0.76),致命性 CVD:0.77(0.80),致命性非 CVD:0.74(0.72),非致命性 CHD 后生存:0.68(0.67),非致命性 CBVD 后生存:0.65(0.66))。一般来说,我们的模型预测与 SHHEC 重叠的苏格兰随机他汀类药物试验人群的观察性事件发生率相当。在应用校准因子后,我们对预期寿命的预测与最近的国家生命表发布的数据非常接近。

结论

我们的模型可用于估计初级预防干预措施对预期寿命的影响,并评估干预措施对不平等的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07e8/4316925/26012d8cda4e/heartjnl-2014-305637f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07e8/4316925/5082842d9fb3/heartjnl-2014-305637f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07e8/4316925/905608854c0d/heartjnl-2014-305637f02a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07e8/4316925/26012d8cda4e/heartjnl-2014-305637f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07e8/4316925/5082842d9fb3/heartjnl-2014-305637f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07e8/4316925/905608854c0d/heartjnl-2014-305637f02a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07e8/4316925/26012d8cda4e/heartjnl-2014-305637f03.jpg

相似文献

1
A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation.考虑社会经济剥夺因素的心血管疾病政策模型,用于预测预期寿命。
Heart. 2015 Feb;101(3):201-8. doi: 10.1136/heartjnl-2014-305637. Epub 2014 Oct 16.
2
Brazilian Analytical Decision Model for Cardiovascular Disease: An Adaptation of the Scottish Cardiovascular Disease Policy Model.
Value Health Reg Issues. 2018 Dec;17:210-216. doi: 10.1016/j.vhri.2018.01.002. Epub 2018 Nov 28.
3
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.长期心血管风险和他汀类药物治疗对社会经济不平等的影响:一个微观模拟模型。
Br J Gen Pract. 2024 Feb 29;74(740):e189-e198. doi: 10.3399/BJGP.2023.0198. Print 2024 Mar.
4
A cardiovascular disease policy model: part 2-preparing for economic evaluation and to assess health inequalities.一种心血管疾病政策模型:第2部分——为经济评估做准备并评估健康不平等状况。
Open Heart. 2016 Jun 10;3(1):e000140. doi: 10.1136/openhrt-2014-000140. eCollection 2016.
5
6
Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions.个体终生心血管风险预测及潜在治疗获益:LIFE-CVD2 模型在四个欧洲风险地区的开发和重新校准。
Eur J Prev Cardiol. 2024 Oct 10;31(14):1690-1699. doi: 10.1093/eurjpc/zwae174.
7
A systematic review and economic evaluation of statins for the prevention of coronary events.他汀类药物预防冠状动脉事件的系统评价与经济学评估
Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. doi: 10.3310/hta11140.
8
Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study.为无症状个体进行他汀类药物治疗的终生获益的个体化预测:一项建模研究。
PLoS Med. 2012;9(12):e1001361. doi: 10.1371/journal.pmed.1001361. Epub 2012 Dec 27.
9
A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease.中重度慢性肾脏病心血管疾病的政策模型
Heart. 2017 Dec;103(23):1880-1890. doi: 10.1136/heartjnl-2016-310970. Epub 2017 Aug 5.
10
Diabetes and number of years of life lost with and without cardiovascular disease: a multi-state homogeneous semi-Markov model.糖尿病与伴有和不伴有心血管疾病的预期寿命损失年数:多状态同质半马尔可夫模型。
Acta Diabetol. 2018 Mar;55(3):253-262. doi: 10.1007/s00592-017-1083-x. Epub 2018 Jan 3.

引用本文的文献

1
Policy models for preventative interventions in cardiometabolic diseases: a systematic review.心血管代谢疾病预防干预的政策模型:一项系统综述
BMC Health Serv Res. 2025 May 2;25(1):635. doi: 10.1186/s12913-025-12781-y.
2
Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis.替代级联检测方案用于识别和管理家族性高胆固醇血症患者:系统评价、定性研究和成本效益分析。
Health Technol Assess. 2023 Oct;27(16):1-140. doi: 10.3310/CTMD0148.
3
Development and Validation of the US Diabetes, Obesity, Cardiovascular Disease Microsimulation (DOC-M) Model: Health Disparity and Economic Impact Model.

本文引用的文献

1
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.1990年和2010年20个年龄组中235种死因的全球和区域死亡率:全球疾病负担研究2010的系统分析
Lancet. 2012 Dec 15;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0.
2
Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model.验证一种模型,以研究改变心血管疾病 (CVD) 风险因素对 CVD 负担的影响:鹿特丹缺血性心脏病和中风计算机模拟 (RISC) 模型。
BMC Med. 2012 Dec 6;10:158. doi: 10.1186/1741-7015-10-158.
3
美国糖尿病、肥胖症、心血管疾病微观模拟模型(DOC-M)的开发和验证:健康差异和经济影响模型。
Med Decis Making. 2023 Oct-Nov;43(7-8):930-948. doi: 10.1177/0272989X231196916. Epub 2023 Oct 16.
4
Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease.超越 10 年风险:他汀类药物用于心血管疾病一级预防的成本效益分析。
Circulation. 2022 Apr 26;145(17):1312-1323. doi: 10.1161/CIRCULATIONAHA.121.057631. Epub 2022 Mar 7.
5
Linking agroecosystems producing farmed seafood with food security and health status to better address the nutritional challenges in Bangladesh.将生产养殖海产品的农业生态系统与食品安全和健康状况联系起来,以更好地应对孟加拉国的营养挑战。
Public Health Nutr. 2019 Nov;22(16):2941-2949. doi: 10.1017/S1368980019002295. Epub 2019 Sep 5.
6
Transparency in Decision Modelling: What, Why, Who and How?透明度决策模型:是什么、为什么、谁和如何?
Pharmacoeconomics. 2019 Nov;37(11):1355-1369. doi: 10.1007/s40273-019-00819-z.
7
Mechanical circulatory support for refractory cardiogenic shock post-acute myocardial infarction-a decade of lessons.急性心肌梗死后难治性心源性休克的机械循环支持——十年经验教训
J Thorac Dis. 2019 Feb;11(2):542-548. doi: 10.21037/jtd.2019.01.21.
8
A cardiovascular disease policy model: part 2-preparing for economic evaluation and to assess health inequalities.一种心血管疾病政策模型:第2部分——为经济评估做准备并评估健康不平等状况。
Open Heart. 2016 Jun 10;3(1):e000140. doi: 10.1136/openhrt-2014-000140. eCollection 2016.
9
Using electronic health records to predict costs and outcomes in stable coronary artery disease.利用电子健康记录预测稳定型冠状动脉疾病的成本和预后。
Heart. 2016 May 15;102(10):755-62. doi: 10.1136/heartjnl-2015-308850. Epub 2016 Feb 10.
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.
模型化良好的研究实践概述:ISPOR-SMDM 模型化良好的研究实践工作组的报告——1.
Value Health. 2012 Sep-Oct;15(6):796-803. doi: 10.1016/j.jval.2012.06.012.
4
Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study.全人群心血管疾病预防的效果和成本效益:建模研究。
BMJ. 2011 Jul 28;343:d4044. doi: 10.1136/bmj.d4044.
5
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.辛伐他汀在来自20536人的随机试验的一系列风险组和年龄组中的终生成本效益。
BMJ. 2006 Dec 2;333(7579):1145. doi: 10.1136/bmj.38993.731725.BE. Epub 2006 Nov 10.
6
Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC).将社会剥夺和家族史纳入心血管风险评估:来自苏格兰心脏健康扩展队列(SHHEC)的ASSIGN评分
Heart. 2007 Feb;93(2):172-6. doi: 10.1136/hrt.2006.108167. Epub 2006 Nov 7.
7
Coronary heart disease policy models: a systematic review.冠心病政策模型:一项系统综述。
BMC Public Health. 2006 Aug 18;6:213. doi: 10.1186/1471-2458-6-213.
8
Apparent and internal validity of a Monte Carlo-Markov model for cardiovascular disease in a cohort follow-up study.
Med Decis Making. 2006 Mar-Apr;26(2):134-44. doi: 10.1177/0272989X05284103.
9
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.英国联合学会临床实践中预防心血管疾病指南2:联合英国学会指南
Heart. 2005 Dec;91 Suppl 5(Suppl 5):v1-52. doi: 10.1136/hrt.2005.079988.
10
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.辛伐他汀在不同血管疾病风险人群中的成本效益:一项针对20536名个体的随机试验的经济分析
Lancet. 2005;365(9473):1779-85. doi: 10.1016/S0140-6736(05)63014-0.